Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Advanced Vision Research names Donnenfield CEO: Advanced Vision Research promotes Neil D. Donnenfield to CEO and board member, the Woburn, Mass.-based marketer and distributor of OTC eye drop line TheraTears says in a Feb. 5 release. Donnenfield joins the firm after the sudden death in August of AVR's founder and most recent CEO, Jeffrey P. Gilbard. Donnenfield, who worked at Procter & Gamble and NutraMax Products, has served since 2005 as AVR's VP of global sales and marketing. "We are eager to introduce revolutionary new products that are already in the pipeline, and look forward to the development of new advances in eye care treatment that improve patients' lives," Donnenfield said in the release

You may also be interested in...



People In Brief

DuPont elbows out Danisco execs

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel